Objective. The efficacy and safety of generic Atorvastatin in patients with chronic obstructive pulmonary diseases (COPD) and/or asthma combined with hyperlipidemia were evaluated.

Materials and methods. 73 participants receiving standard COPD/asthma treatment were enrolled. The patients were randomly assigned to receive Atorvastatin (produced by “Belmedpreparaty”, Belarus) 20 mg per day for 24 weeks in addition (n=46) or the standard treatment only (n=27).

Results. Generic Atorvastatin in COPD patients was determined to reduce the total cholesterol (TC) by 26% (р=0.005), the low-density lipoprotein cholesterol (LDL-C) by 17% (p=0.26), the triglycerides (TG) by 14% (p=0.047). The adverse events incidence was 11%, the frequency of Atorvastatin discontinuation was 6.5%. The generic Atorvastatin was found to be safe and effective in COPD patients the safety and efficacy profile being similar to the foreign analogues.